SubsidieMeestersRevolutionary silk-based bioink for 3D printing of ex vivo bone marrow models to advance drug development and personalized medicine
The SILKink project aims to develop a silk-based bioink for 3D printing bone marrow tissue models to enhance stem cell culture and advance drug development and personalized medicine.
Projectdetails
Aim
The SILKink project aims to develop a breakthrough biocompatible hydrogel, i.e., a bioink, to 3D print bone marrow tissue models that can be used for robust culture of human stem cells. The use of silk as the basis for novel bioinks (SILKink) helps to recreate tailored bone marrow-like microenvironments that will enable new applications in drug development and personalized medicine for bone marrow diseases.
Here, we aim to optimize and validate SILKink, further define the business opportunity, and found an investment-ready spin-off company to commercialize SILKink.
Unmet Need
Bone marrow stem cells are fragile and require highly specific surroundings to survive and differentiate. Therefore, the presence of a soft tissue environment mimicking the human bone marrow is critical for reproducible culturing of these cells.
There is a large unmet need for reproducible solutions that mimic the soft tissue of the bone marrow to allow advancements in drug development and personalized medicine approaches for bone marrow diseases.
Solution
We will develop SILKink: a revolutionary bioink that is uniquely based on silk to closely mimic the 3D soft tissue environment of the bone marrow.
SILKink will provide a matrix that supports all bone marrow cells including hematopoietic stem and progenitor cells and allows for 3D printing ex vivo bone marrow stem cell models in the shape or volume desired.
Consortium
University of Pavia (UNIPV) and partner CELLINK have developed the SILKink prototype during the FET Open project SilkFUSION and co-own the background IP.
Partner Catalyze-Group – Venture Building Team (CAT) will bring commercial expertise to develop an optimal market access strategy for SILKink.
- UNIPV will be responsible for SILKink optimization, manufacturing, and validation.
- CELLINK will be involved in product optimization and responsible for product development.
- CAT will assist UNIPV with founding a spin-off company to commercialize SILKink and making it investment-ready.
Financiële details & Tijdlijn
Financiële details
| Subsidiebedrag | € 2.494.687 |
| Totale projectbegroting | € 2.494.687 |
Tijdlijn
| Startdatum | 1-6-2023 |
| Einddatum | 31-5-2026 |
| Subsidiejaar | 2023 |
Partners & Locaties
Projectpartners
- UNIVERSITA DEGLI STUDI DI PAVIApenvoerder
- CELLINK BIOPRINTING AB
- Catalyze B.V.
Land(en)
Geen landeninformatie beschikbaar
Vergelijkbare projecten binnen EIC Transition
| Project | Regeling | Bedrag | Jaar | Actie |
|---|---|---|---|---|
Targeting cardiac fibrosis with next generation RNA therapeuticsFIBREX aims to develop an innovative ncRNA-based antisense oligonucleotide therapy targeting Meg3 to reverse cardiac fibrosis and treat heart failure, advancing towards clinical readiness. | EIC Transition | € 2.499.482 | 2022 | Details |
automated in-line separatioN and dEtection of eXtracellular vesicles for liqUid biopsy applicationSThe NEXUS project aims to industrialize a customizable platform for the separation and analysis of extracellular vesicles from biofluids, enhancing cancer diagnostics and monitoring. | EIC Transition | € 2.497.750 | 2022 | Details |
Predictive REagent-Antibody Replacement Technology stage 2-TranslationPRe-ART-2T aims to advance predictive antibody technology to TRL6, replacing low-quality monoclonal antibodies with high-performing synthetic alternatives, and attract ~€20M in investment. | EIC Transition | € 800.000 | 2022 | Details |
Advancing a vaccine targeting genetic amyotrophic lateral sclerosis (C9orf72 ALS) to the clinical stageDeveloping a poly-GA peptide vaccine to reduce protein aggregation and motor deficits in C9orf72 ALS, aiming for clinical evaluation and market entry through strategic partnerships. | EIC Transition | € 2.499.810 | 2022 | Details |
Targeting cardiac fibrosis with next generation RNA therapeutics
FIBREX aims to develop an innovative ncRNA-based antisense oligonucleotide therapy targeting Meg3 to reverse cardiac fibrosis and treat heart failure, advancing towards clinical readiness.
automated in-line separatioN and dEtection of eXtracellular vesicles for liqUid biopsy applicationS
The NEXUS project aims to industrialize a customizable platform for the separation and analysis of extracellular vesicles from biofluids, enhancing cancer diagnostics and monitoring.
Predictive REagent-Antibody Replacement Technology stage 2-Translation
PRe-ART-2T aims to advance predictive antibody technology to TRL6, replacing low-quality monoclonal antibodies with high-performing synthetic alternatives, and attract ~€20M in investment.
Advancing a vaccine targeting genetic amyotrophic lateral sclerosis (C9orf72 ALS) to the clinical stage
Developing a poly-GA peptide vaccine to reduce protein aggregation and motor deficits in C9orf72 ALS, aiming for clinical evaluation and market entry through strategic partnerships.
Vergelijkbare projecten uit andere regelingen
| Project | Regeling | Bedrag | Jaar | Actie |
|---|---|---|---|---|
A novel support material for 3D bioprinting and post-printing tissue growth: Print and GrowThe "Print and Grow" project aims to enhance 3D bioprinting stability and viability of tissue constructs through a novel microgel support, optimizing for diverse tissue types and in vivo applications. | ERC POC | € 150.000 | 2022 | Details |
PRInted Symbiotic Materials as a dynamic platform for Living Tissues productionPRISM-LT aims to develop a flexible bioprinting platform using hybrid living materials to enhance stem cell differentiation with engineered helper cells for biomedical and food applications. | EIC Pathfinder | € 2.805.403 | 2022 | Details |
Human based bioinks to engineer physiologically relevant tissuesHumanINK aims to validate human-based bioinks for 3D bioprinting, creating advanced cell culture environments to enhance drug development and reduce reliance on animal testing. | ERC POC | € 150.000 | 2022 | Details |
Universal 3D printer bioink for Type 1 diabetes cell therapyUniink aims to develop a high-throughput 3D bioprinting method for producing consistent, insulin-secreting microspheres as a viable alternative to islet transplantation for Type 1 Diabetes treatment. | ERC POC | € 150.000 | 2024 | Details |
A novel support material for 3D bioprinting and post-printing tissue growth: Print and Grow
The "Print and Grow" project aims to enhance 3D bioprinting stability and viability of tissue constructs through a novel microgel support, optimizing for diverse tissue types and in vivo applications.
PRInted Symbiotic Materials as a dynamic platform for Living Tissues production
PRISM-LT aims to develop a flexible bioprinting platform using hybrid living materials to enhance stem cell differentiation with engineered helper cells for biomedical and food applications.
Human based bioinks to engineer physiologically relevant tissues
HumanINK aims to validate human-based bioinks for 3D bioprinting, creating advanced cell culture environments to enhance drug development and reduce reliance on animal testing.
Universal 3D printer bioink for Type 1 diabetes cell therapy
Uniink aims to develop a high-throughput 3D bioprinting method for producing consistent, insulin-secreting microspheres as a viable alternative to islet transplantation for Type 1 Diabetes treatment.